Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 studyPhilip A. Philip, Pascal Hammel, Edward Kim et al.|The Lancet. Gastroenterology & hepatology|2020Cited by 249
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases OnlyJohanna C. Bendell, Anthony A. Meluch, Ahmed Zakari et al.|The Oncologist|2016Cited by 20
nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT TrialP. A. Philip, Pascal Hammel, Jill Lacy et al.|Annals of Oncology|2017Cited by 3